-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Neutral on Conmed, Lowers Price Target to $40

Benzinga·04/30/2026 22:30:22
Listen to the news
JP Morgan analyst Robbie Marcus maintains Conmed (NYSE:CNMD) with a Neutral and lowers the price target from $43 to $40.